CN103127511A - Novel drug composition for curing hepatitis c virus - Google Patents
Novel drug composition for curing hepatitis c virus Download PDFInfo
- Publication number
- CN103127511A CN103127511A CN2013100492938A CN201310049293A CN103127511A CN 103127511 A CN103127511 A CN 103127511A CN 2013100492938 A CN2013100492938 A CN 2013100492938A CN 201310049293 A CN201310049293 A CN 201310049293A CN 103127511 A CN103127511 A CN 103127511A
- Authority
- CN
- China
- Prior art keywords
- hcv
- ezetimibe
- ribavirin
- agent
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to a novel antiviral drug composition and a method for curing hepatitis c virus (HCV) infection by using the novel type antiviral drug composition. The novel antiviral drug composition comprises 1 - (4-fluorine phenyl) - (3R)- [3 - (4 - fluorine phenyl) - (3S) - hydroxypropyl] - (4S) - (4 - hydroxypropyl) - 2-acrylic amide (ezetimibe, structural formula presented as graph 1) or acceptable derivatives in pharmaceutic preparation thereof, and an HCV resisting drug which is a drug composition selected from one kind or multiple kinds of boceprecir (BOC), telaprevir (TVR), pegylated interferon alpha (PEG - IFN alpha), interferon (IFNO) and ribavirin.
Description
Technical field:
the present invention relates to a kind of novel antiviral pharmaceutical composition, said composition comprises 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone (ezetimibe, Ezetimibe, structural formula is seen Fig. 1) or its pharmaceutical preparation on acceptable derivates, be selected from a rich match Wei Boceprevir (BOC) with the medicine of anti-HCV (hepatitis C virus), VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), the pharmaceutical composition of one or more in ribavirin (Ribavirin) and be used for the treatment of the method that HCV infects, belong to field of pharmaceutical preparations.
Background technology:
Hepatitis C, referred to as hepatitis C, hepatitis C, a kind of viral hepatitis that causes that infected by hepatitis C virus (Hepatitis C virus, HCV), mainly through blood transfusion, acupuncture, the propagation such as drug abuse, according to World Health Organization's statistics, the infection rate of global HCV is about 3%, estimate that approximately 1.8 hundred million people have infected HCV, annual new hepatitis C case is 3.5 ten thousand examples approximately.It is global popular that hepatitis C is, and can cause the necrosis of liver chronic inflammatory disease and fibrosis, and some patients were can develop into even hepatocarcinoma (HCC) of liver cirrhosis.Some data show infect relevant mortality rate (death that liver failure and hepatocarcinoma cause) to HCV in following 20 years and will continue to increase, and are very harmful to patient's health and lives, become serious society and public health problem.
Hepatitis C virus belongs to flaviviridae, is a kind of single strand plus RNA virus, is the one of the main reasons that causes hepatic disease.Although it is asymptomatic that the patient of actute infection shows as, about 80% patient reaches and follows other hepatic disease because removing virus thereby change Chronic Liver into, comprises hepatic steatosis shape, insulin resistant, hepatic fibrosis, liver cirrhosis and hepatocellular carcinoma.Become serious public health problem although HCV infects, still there is no the propagation of effective vaccine blocking-up HCV at present.
At first the HCV host cells infected is that virion is combined with the series of receptors of cell surface, is then completed by receptor mediated endocytosis.These receptors comprise four molecule crosslinked epicyte protein CD81, the scavenger receptor B I of family type (SR-B I), then Tight junction protein claudin-1 and tight junction protein claudin-6 merge to infect host cell by the mediation endocytosis of the clathrin between HCV peplos and nuclear membrane and two albuminoids.In addition, low density lipoprotein receptor, asialoglycoprotein receptor, protocadherin β 5, and glycosaminoglycans participates in infecting of virus, but there also do not have these albumen of enough theoretical proofs to be that HCV infects host cell at present to be necessary.
The interferon and the ribavirin therapeutic alliance HCV that adopt at present, but this therapeutic alliance has certain toxic and side effects, border effect and make its scope of application limited.In addition, the antiviral effect that proves a series of HCV viral inhibitors with the virus replication method for measuring is described in US2008/0161324.But these compounds can not stop infecting of HCV virus and propagate.Therefore, it is imperative (as: suppressing the intrusion of virus) from other aspects of viral life cycle and seek novel and potential antiviral target spot.
The research group latest find is arranged a few days ago, and the NPC1L1 albumen in human body has been brought into play important function in the hepatitis c virus infection process, and the function of this protein of containment may help the prevention infection hepatitis C virus.Code name can be played the part of the receptor role for the human body protein of " NPC1L1 " in the hepatitis c virus infection process, thereby it can be combined with hepatitis C virus and causes infection.If " can stop NPC1L1 protein to play a role, the efficiency of infection of hepatitis C virus is significantly reduced, be expected to develop accordingly the hepatitis C that makes new advances in the future and prevent and treat method.
NPC1L1 is the albumen of a class and NPC1 homology, is present on the cell of liver and small intestinal.Before this research finds, under the help of other protein, NPC1L1 can be with the cholesterol transport in food to cell, then is stored in liver.Absorb the function of cholesterol due to NPC1L1, medical circle has been developed the medicine ezetimibe that plays a role to treat hyperlipidemia by containment NPC1L1 protein.
Ezetimibe, a class 2-aza cyclo-butanone medicine, the FDA approval is used for lipidemia and reduces the indication of cholesterol; Confirmed that this medicine can suppress the absorption of organism inner cholesterol, also can reduce simultaneously the content of T-CHOL and low density cholesterol in blood plasma.Data show, albumen Niemannn-Pick C1-like1 (NPC1L1) targeting effect and ezetimibe in cell.
The present invention uses cell model and animal hepatitis C model in early-stage Study, investigated ezetimibe (Ezetimibe), structural formula is seen Fig. 1), be selected from a rich match Wei (Boceprevir) with the medicine of anti-HCV (hepatitis C virus), VX-960 (Telaprevir), long-acting interferon (PEG-IFN α), interferon (IFN α), external, interior (per os and the Bolos intravenous administration) anti-hcv activity of body of the pharmaceutical composition of one or more in ribavirin (Ribavirin).Experimental result shows, ezetimibe is united other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them all has stronger anti-HCV activity, can more effectively suppress HVC intrusion in the healthy cell by carrier NPC1L1 protein, copying of HCV in cell under condition of culture also had significant inhibitory action.Oral or injection gives ezetimibe and unites other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them, all can significantly reduce HCV at the hepatic tissue of infection animal and the copy number in blood, significantly improve HCV infection animal liver tissue lesions degree, alleviate liver inflammatory necrosis and fibrosis.
The invention provides a kind of new, than more effectively method and the pharmaceutical preparation of drug combination treatment hepatitis C disease of existing therapeutic scheme.
Summary of the invention:
The object of the present invention is to provide a kind of by acceptable derivates in 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone or its pharmaceutical preparation, with the compositions of another one or more anti-HCV medicament and be used for the treatment of the method that HCV infects, belong to field of pharmaceutical preparations.
The derivant of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone can refer to its pharmaceutically acceptable salt, ester.
Anti-HCV medicament refers to a rich match Wei (Boceprevir), VX-960 (Telaprevir), long-acting interferon (PEG-IFN α), interferon (IFN α), ribavirin (Ribavirin, 1-β-D-RIBOSE-1,2,4-triazole-3-hydroxyl amide) and pharmaceutically acceptable salt, ester.
pharmaceutical composition of the present invention is selected from ezetimibe and the rich compositions of matching a Wei, the compositions of ezetimibe and VX-960, the compositions of ezetimibe and long-acting interferon, the compositions of ezetimibe and interferon, the compositions of ezetimibe and ribavirin, ezetimibe, the compositions of a rich match Wei and interferon, ezetimibe, the compositions of VX-960 and interferon, ezetimibe, the compositions of ribavirin and interferon, ezetimibe, the compositions of ribavirin and interferon, ezetimibe, the compositions of ribavirin and long-acting interferon, ezetimibe, the compositions of VX-960 and long-acting interferon, ezetimibe, the compositions of a rich match Wei and long-acting interferon, ezetimibe, the compositions of a rich match Wei and ribavirin, ezetimibe, the compositions of VX-960 and ribavirin, be preferably ezetimibe and the rich compositions of matching a Wei, the compositions of ezetimibe and VX-960, the compositions of ezetimibe and ribavirin, the compositions of ezetimibe, ribavirin and long-acting interferon, the compositions of ezetimibe and ribavirin more preferably, the compositions of ezetimibe, ribavirin and long-acting interferon.
The pharmaceutically acceptable salt of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone and anti-HCV medicament comprises that those come from pharmaceutically acceptable inorganic and acylate.Suitable acid comprises hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, acetic acid, lactic acid, salicylic acid, succinic acid, p-methyl benzenesulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid and benzenesulfonic acid.Other acid although its salt is not pharmaceutically acceptable salt, can be used as intermediate for the preparation of the compounds of this invention or its pharmaceutically acceptable acid and salify as oxalic acid.
The compositions that the present invention provides ezetimibe and another one or more anti-HCV medicament to exist with collaborative ratio on the other hand.
In one embodiment of the present of invention, the synergism ratio of the rich match of ezetimibe and another an anti-HCV medicament Wei is 1: 1000-1: 1, be preferably 1: 50-1: 1.
In an alternative embodiment of the invention, the synergism ratio of ezetimibe and another anti-HCV medicament VX-960 is 1: 1000-1: 1, be preferably 1: 100-1: 1.
In an alternative embodiment of the invention, the synergism ratio of ezetimibe and another anti-HCV medicament ribavirin is 1: 100-1: 1, be preferably 1: 10-1: 1.
In an alternative embodiment of the invention, ezetimibe and another anti-HCV medicament are selected from a rich match Wei, VX-960, and ribavirin is added interferon and is formed three administering drug combinations, and wherein the dosage of interferon is by medically conventional dosage administration.
On unit dose, in the present composition, the dosage of ezetimibe is 1-100mg, and the dosage of a rich match Wei is 10-2000mg, and the dosage of VX-960 is 10-2000mg, and the dosage of ribavirin is 10-1000mg; Be preferably ezetimibe 5-50mg, the dosage of a rich match Wei is 50-1200mg, and the dosage of VX-960 is 50-1200mg, and the dosage of ribavirin is 10-500mg.
Concrete dosage, for all ages and classes, different physique and sex difference have difference, and concrete administered dose is at this moment determined according to actual state of an illness situation by the medical personnel.
in the present invention, when using ezetimibe and another one or more anti-HCV medicament combination treatment viral hepatitis, ezetimibe and another anti-HCV medicament can be to be combined in together in a unit dose to carry out administration, as both or three are mixed and made into the unit dose tablet form, capsule form, can be also to be present in separately in preparation separated from one another, as making merely the ezetimibe tablet, a rich match Wei tablet or ribavirin injection, give both in sequencing, order administration in this way, the delay administration of second active ingredient should not reduce the synergism between this active component combination.Will also be understood that to be, administration no matter simultaneously or sequentially, ezetimibe, a rich match Wei or its pharmaceutically acceptable derivates can with independent or any combining form administration, be preferably administration simultaneously or with the administration of independent form order, most preferably be administration simultaneously.
In the present invention, compositions can be by oral, per nasal, oral cavity suction, eye, rectum, part (comprising in percutaneous, cheek and the Sublingual), vagina or non-rectum (comprising subcutaneous, muscle, vein and Intradermal) mode administration.In these form of medication, be generally single dose form, can be by as long as the preparation method preparation that the field is known, usually, these preparations can be by with active component and liquid-carrier or finely dispersed solid carrier or both are all even closely is mixed with.
In compositions of the present invention, also can comprise other pharmaceutically acceptable carrier additives.type for described additive does not have concrete restriction, it can be additive conventional in this area, specifically be selected from pharmaceutically acceptable solvent, propellant, solubilizing agent, cosolvent, emulsifying agent, coloring agent, adhesive, disintegrating agent, filler, lubricant, wetting agent, osmotic pressure regulator, stabilizing agent, fluidizer, correctives, antiseptic, suspending agent, coating material, aromatic, anti-adhesive, integrated agent, penetration enhancer, the pH value regulator, buffer agent, plasticizer, surfactant, foaming agent, defoamer, thickening agent, inclusion agents, wetting agent, absorbent, diluent, flocculating agent and deflocculant, filter aid, discharge blocker etc.
In the present invention, consumption and the combining form for other additives do not have any restriction.
The present invention uses cell model and animal hepatitis C model in early-stage Study, the medicine of having investigated ezetimibe and anti-HCV (hepatitis C virus) is selected from a rich match Wei Boceprevir (BOC), VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), external, interior (per os and the Bolos intravenous administration) anti-hcv activity of body of the pharmaceutical composition of one or more in ribavirin (Ribavirin).Experimental result shows, ezetimibe is united other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them all has stronger anti-HCV activity, can more effectively suppress HVC intrusion in the healthy cell by carrier NPC1L1 protein, copying of HCV in cell under condition of culture also had significant inhibitory action.Oral or injection gives ezetimibe and unites other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them, all can significantly reduce HCV at the hepatic tissue of infection animal and the copy number in blood, significantly improve HCV infection animal liver tissue lesions degree, alleviate liver inflammatory necrosis and fibrosis.
The present invention finds in research process because the drug mechanism of the known treatment hepatitis C of ezetimibe and other is not identical, be not limited to ezetimibe and a rich match Wei Boceprevir (BOC) so the present invention includes, VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), ribavirin (Ribavirin) drug combination, ezetimibe also can be with the medication combined medication of other mechanisms of action to improve the therapeutic effect to hepatitis C.
Description of drawings:
Accompanying drawing 1 is 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone (ezetimibe, structural formula Ezetimibe).
The specific embodiment:
in the present invention, when using ezetimibe and another one or more anti-HCV medicament combination treatment viral hepatitis, ezetimibe and another anti-HCV medicament can be to be combined in together in a unit dose to carry out administration, as both or three are mixed and made into the unit dose tablet form, capsule form, can be also to be present in separately in preparation separated from one another, as making merely the ezetimibe tablet, a rich match Wei tablet or ribavirin injection, give both in sequencing, order administration in this way, the delay administration of second active ingredient should not reduce the synergism between this active component combination.Will also be understood that to be, administration no matter simultaneously or sequentially, ezetimibe, a rich match Wei or its pharmaceutically acceptable derivates can with independent or any combining form administration, be preferably administration simultaneously or with the administration of independent form order, most preferably be administration simultaneously.
The present invention finds in research process because the drug mechanism of the known treatment hepatitis C of ezetimibe and other is not identical, be not limited to ezetimibe and a rich match Wei Boceprevir (BOC) so the present invention includes, VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), ribavirin (Ribavirin) drug combination, ezetimibe also can be with the medication combined medication of other mechanisms of action to improve the therapeutic effect to hepatitis C.
In the present invention, compositions can be by oral, per nasal, oral cavity suction, eye, rectum, part (comprising in percutaneous, cheek and the Sublingual), vagina or non-rectum (comprising subcutaneous, muscle, vein and Intradermal) mode administration.In these form of medication, be generally single dose form, can be by as long as the preparation method preparation that the field is known, usually, these preparations can be by with active component and liquid-carrier or finely dispersed solid carrier or both are all even closely is mixed with.
In compositions of the present invention, also can comprise other pharmaceutically acceptable carrier additives.type for described additive does not have concrete restriction, it can be additive conventional in this area, specifically be selected from pharmaceutically acceptable solvent, propellant, solubilizing agent, cosolvent, emulsifying agent, coloring agent, adhesive, disintegrating agent, filler, lubricant, wetting agent, osmotic pressure regulator, stabilizing agent, fluidizer, correctives, antiseptic, suspending agent, coating material, aromatic, anti-adhesive, integrated agent, penetration enhancer, the pH value regulator, buffer agent, plasticizer, surfactant, foaming agent, defoamer, thickening agent, inclusion agents, wetting agent, absorbent, diluent, flocculating agent and deflocculant, filter aid, discharge blocker etc.
In the present invention, consumption and the combining form for other additives do not have any restriction.
Further describe the pharmaceutical dosage forms of compositions related in the present invention below by specific embodiment, but do not limit the scope of the invention.
1, in a preferred embodiment of the present invention, the described compositions that contains ezetimibe and lamivudine comprises:
The ezetimibe of 10 weight portions;
The ribavirin of 250 weight portions;
The microcrystalline Cellulose of 100 weight portions;
The lactose monohydrate of 40 weight portions;
The magnesium stearate of 4 weight portions;
Appropriate 3%PVP K
30Aqueous solution is done binding agent.
The described compositions that contains ezetimibe and ribavirin can be prepared into various solid dosage formss, comprises tablet, capsule and granule.
The described preparation method that contains the composition tablet of ezetimibe and ribavirin adopts conventional method for preparing tablet thereof all can realize, comprises wet granule compression tablet method, dry granulation tabletting method or direct powder compression method.
The described composition capsule that contains ezetimibe and ribavirin, the preparation method of its content adopts conventional preparation method of granules all can realize, comprises wet granulation process, dry granulation method or powder direct mixing method.
The described preparation method that contains the composition granule of ezetimibe and ribavirin adopts conventional preparation method of granules all can realize, comprises wet granulation process, dry granulation method.
2, in another preferred embodiment of the present invention, the described compositions that contains ezetimibe and VX-960 comprises:
The ezetimibe of 5 weight portions;
The VX-960 of 375 weight portions;
The sucrose of 20 weight portions;
The microcrystalline Cellulose of 50 weight portions;
The pregelatinized Starch of 50 weight portions;
The magnesium stearate of 5 weight portions;
Appropriate 3%PVP K
30Aqueous solution is done binding agent.
The described compositions that contains ezetimibe and VX-960 can be prepared into various solid dosage formss, comprises tablet, capsule and granule.
The described preparation method that contains the composition tablet of ezetimibe and VX-960 adopts conventional method for preparing tablet thereof all can realize, comprises wet granule compression tablet method, dry granulation tabletting method or direct powder compression method.
The described composition capsule that contains ezetimibe and VX-960, the preparation method of its content adopts conventional preparation method of granules all can realize, comprises wet granulation process, dry granulation method or powder direct mixing method.
The described preparation method that contains the composition granule of ezetimibe and VX-960 adopts conventional preparation method of granules all can realize, comprises wet granulation process, dry granulation method.
The present invention uses cell model and animal hepatitis C model in early-stage Study, the medicine of having investigated ezetimibe and anti-HCV (hepatitis C virus) is selected from a rich match Wei Boceprevir (BOC), VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), external, interior (per os and the Bolos intravenous administration) anti-hcv activity of body of the pharmaceutical composition of one or more in ribavirin (Ribavirin).Experimental result shows, ezetimibe is united other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them all has stronger anti-HCV activity, can more effectively suppress HVC intrusion in the healthy cell by carrier NPC1L1 protein, copying of HCV in cell under condition of culture also had significant inhibitory action.Oral or injection gives ezetimibe and unites other any one or more anti-HCV medicaments, with respect to the existing single anti-HCV medicament of single utilization, or the composite reagent between them, all can significantly reduce HCV at the hepatic tissue of infection animal and the copy number in blood, significantly improve HCV infection animal liver tissue lesions degree, alleviate liver inflammatory necrosis and fibrosis.
Claims (9)
1. compositions comprises in the agent of a cholesterol decrease uptake or its pharmaceutical preparation acceptable derivates on acceptable derivates and one or several anti-HCV medicament or its pharmaceutical preparation.
2. desired compositions according to claim 1, wherein the agent of cholesterol decrease uptake is 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone or its pharmaceutically acceptable salt.
3. desired compositions according to claim 1, wherein the HCV medicine is selected from a rich match Wei Boceprevir (BOC), VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), one or more in ribavirin (Ribavirin) or its pharmaceutical preparation in acceptable derivates.
4. a pharmaceutical composition comprises in claim 1-3 in the agent of defined cholesterol decrease uptake or its pharmaceutical preparation acceptable derivates on acceptable derivates and one or several anti-HCV medicament or its pharmaceutical preparation, and acceptable carrier in pharmaceutical preparation.
5. one kind is used for the treatment of mammal and comprises that the people suffers from or is subject to the method that HCV infects, and comprises in defined cholesterol decrease uptake agent in claim 1 or its pharmaceutical preparation the use of uniting of acceptable derivates on acceptable derivates and one or several anti-HCV medicament and pharmaceutical preparation thereof.
6. desired method according to claim 5, the agent of cholesterol decrease uptake and one or several anti-HCV medicament are to use simultaneously.
7. desired method according to claim 5, the agent of cholesterol decrease uptake and one or several anti-HCV medicament use in succession.
8. any one desired method according to claim 5-7, wherein the agent of cholesterol decrease uptake is acceptable derivates in 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone or its pharmaceutical preparation.
9. any one desired method according to claim 5-7, wherein the HCV medicine is selected from a rich match Wei Boceprevir (BOC), VX-960 Telaprevir (TVR), long-acting interferon (PEG-IFN α), interferon (IFN α), one or more in ribavirin (Ribavirin) or its pharmaceutical preparation in acceptable derivates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100492938A CN103127511A (en) | 2013-02-07 | 2013-02-07 | Novel drug composition for curing hepatitis c virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100492938A CN103127511A (en) | 2013-02-07 | 2013-02-07 | Novel drug composition for curing hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103127511A true CN103127511A (en) | 2013-06-05 |
Family
ID=48488378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100492938A Pending CN103127511A (en) | 2013-02-07 | 2013-02-07 | Novel drug composition for curing hepatitis c virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103127511A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113289018A (en) * | 2020-02-21 | 2021-08-24 | 中国科学院上海药物研究所 | Application of old medicine such as auranofin and composition thereof in resisting single positive strand RNA virus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110171177A1 (en) * | 2008-09-02 | 2011-07-14 | Uprichard Susan L | Compositions and Methods for Inhibiting Entry of a Hepatic Virus |
-
2013
- 2013-02-07 CN CN2013100492938A patent/CN103127511A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110171177A1 (en) * | 2008-09-02 | 2011-07-14 | Uprichard Susan L | Compositions and Methods for Inhibiting Entry of a Hepatic Virus |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113289018A (en) * | 2020-02-21 | 2021-08-24 | 中国科学院上海药物研究所 | Application of old medicine such as auranofin and composition thereof in resisting single positive strand RNA virus |
| CN113289018B (en) * | 2020-02-21 | 2023-08-25 | 中国科学院上海药物研究所 | Application of old medicines such as auranofin and the like and compositions thereof in resisting single positive strand RNA viruses |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9248115B2 (en) | Silibinin component for the treatment of hepatitis | |
| JP5869469B2 (en) | Treatment of liver diseases where iron is involved in the pathogenesis | |
| CN106232136A (en) | For treating the conjoint therapy of HBV infection | |
| RU2010113976A (en) | APPLICATION OF GLP-1 AS A THERAPEUTIC | |
| RU2010114045A (en) | USE OF SFLLR-OH PEPTIDE AND MURAMYL DIPEPTIDE AS A THERAPEUTIC MEDICINE | |
| RU2012136824A (en) | METHODS FOR TREATING HEPATITIS C VIRAL INFECTION | |
| RU2010114047A (en) | APPLICATION OF HUMAN NEUROPEPTIDE AF AS A THERAPEUTIC | |
| RU2010114030A (en) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC | |
| RU2010113992A (en) | UROCORTIN AND CORTICOLIBERIN USE AS A THERAPEUTIC | |
| JP2008515816A (en) | Combination antiviral composition containing castanospermine and method of use thereof | |
| CN102083435A (en) | Telaprevir dosing regimen | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2017514911A5 (en) | ||
| RU2371195C2 (en) | Method of virus infection treatment | |
| RU2002105485A (en) | The use of mycophenolate mofetil in combination with PEG-interferon-α (PEG-IFN-α) | |
| CN103127511A (en) | Novel drug composition for curing hepatitis c virus | |
| EP2959891A1 (en) | Modified release pharmaceutical compositions of sofosbuvir and ribavirin | |
| CN102844028B (en) | The combination of HCV macrocyclic hcv inhibitors, non-nucleoside and nucleoside | |
| CN101489579A (en) | Prophylactic or therapeutic agent for viral disease | |
| RU2010114035A (en) | APPLICATION OF RFRP INDIVIDUALLY OR IN COMBINATION WITH NEUROKININ AS A THERAPEUTIC | |
| CN107308121A (en) | The therapeutic agent of liver regeneration | |
| CN103127512A (en) | Novel drug composition for curing hepatitis B virus | |
| CN104434920B (en) | A kind of pharmaceutical composition treating heart failure and application thereof | |
| JP2021161105A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| Bratcher et al. | How to Manage Patients with HIV/HCV Co-Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130605 |